Stella P Breininger
Overview
Explore the profile of Stella P Breininger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
11
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Walker R, Harrington J, Breininger S, Pickering O, Hill S, Sharpe B, et al.
Br J Surg
. 2024 Apr;
111(4).
PMID: 38630793
No abstract available.
2.
Sharpe B, Hayden A, Manousopoulou A, Cowie A, Walker R, Harrington J, et al.
Cell Rep Med
. 2022 Jun;
3(6):100541.
PMID: 35732148
The chemotherapy resistance of esophageal adenocarcinomas (EACs) is underpinned by cancer cell extrinsic mechanisms of the tumor microenvironment (TME). We demonstrate that, by targeting the tumor-promoting functions of the predominant...
3.
Lang C, Lloyd M, Alyacoubi S, Rahman S, Pickering O, Underwood T, et al.
Cancers (Basel)
. 2022 Mar;
14(5).
PMID: 35267476
Oesophageal cancer (OC) is the ninth most common cancer worldwide. Patients receive neoadjuvant therapy (NAT) as standard of care, but less than 20% of patients with oesophageal adenocarcinoma (OAC) or...
4.
Pickering O, Breininger S, Underwood T, Walters Z
Cancers (Basel)
. 2021 Aug;
13(16).
PMID: 34439236
Oesophageal adenocarcinoma (OAC) has a dismal prognosis, where curable disease occurs in less than 40% of patients, and many of those with incurable disease survive for less than a year...
5.
Izadi F, Sharpe B, Breininger S, Secrier M, Gibson J, Walker R, et al.
Cancers (Basel)
. 2021 Jul;
13(14).
PMID: 34298611
Neoadjuvant therapy followed by surgery is the standard of care for locally advanced esophageal adenocarcinoma (EAC). Unfortunately, response to neoadjuvant chemotherapy (NAC) is poor (20-37%), as is the overall survival...